This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn various ways to maximize credit card points for better rewards. This guide offers proven techniques to enhance your savings.
17,889 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Apple’s next AI chapter hinges on Siri. If the so-called this "siri-ous" problem could derail AI progress, investors ...
Ark Invest discloses a fresh Palantir stake as AI momentum collides with higher yields, prompting debate over whether...
Palo Alto Networks is trading lower as acquisition costs press on near-term guidance, even as AI security bets throug...
A notable analyst warns of a potential slide to $40,000 for Bitcoin, even as other models see a bottom in the $50,000...
The Trade Desk prepares to report quarterly results as investors grapple with a steep stock drop, focusing on revenue...
May data show 7.6 million job openings, topping forecasts and signaling stabilization in the labor market. Thursday's...
Iovance surged this week after robust Q4 results and a Philadelphia manufacturing moat highlighted by a 32 day turnar...
Palantir stock is shaping up for a year-end move as AI demand and expanding government and commercial contracts fuel ...
When a fund exits its Brookdale Senior Living stake, it raises questions about momentum and risk. This guide breaks d...
Meta Platforms signals a cloud compute push, aiming to sell AI capacity directly to enterprises amid a record capex c...
This piece examines which stocks people actually search for and why those trends matter. Learn how to separate curios...